MX386293B - Compuestos de aminoindano y su uso en el tratamiento del dolor. - Google Patents

Compuestos de aminoindano y su uso en el tratamiento del dolor.

Info

Publication number
MX386293B
MX386293B MX2017008878A MX2017008878A MX386293B MX 386293 B MX386293 B MX 386293B MX 2017008878 A MX2017008878 A MX 2017008878A MX 2017008878 A MX2017008878 A MX 2017008878A MX 386293 B MX386293 B MX 386293B
Authority
MX
Mexico
Prior art keywords
compounds
pain treatment
aminoindane
aminoindane compounds
receptor activator
Prior art date
Application number
MX2017008878A
Other languages
English (en)
Inventor
Carl Henry Behrens
Dipanwita Chatterjee
Arun Kuma Hajra
Yigang He
Hui-Yin Li
Tony Priestley
Sonali Rudra
Ashis K Saha
Roger Astbury Smith
Scott Kevin Thompson
Original Assignee
Libertas Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Libertas Bio Inc filed Critical Libertas Bio Inc
Publication of MX386293B publication Critical patent/MX386293B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente solicitud proporciona compuestos de aminoindano novedosos y métodos para preparar y utilizar estos compuestos; estos compuestos son útiles para el tratamiento de dolor y/o picazón al administrarse uno o más de los compuestos a un paciente; los métodos incluyen administrar un compuesto de la fórmula (I) o (II) y un activador del receptor TRPV1; en una modalidad, el activador del receptor TRPV1 es lidocaína.
MX2017008878A 2011-02-18 2012-02-18 Compuestos de aminoindano y su uso en el tratamiento del dolor. MX386293B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161444379P 2011-02-18 2011-02-18
PCT/US2012/025759 WO2012112969A1 (en) 2011-02-18 2012-02-18 Aminoindane compounds and use thereof in treating pain

Publications (1)

Publication Number Publication Date
MX386293B true MX386293B (es) 2025-03-18

Family

ID=45787355

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013009537A MX348961B (es) 2011-02-18 2012-02-18 Compuestos de aminoindano y su uso en el tratamiento del dolor.
MX2017008878A MX386293B (es) 2011-02-18 2012-02-18 Compuestos de aminoindano y su uso en el tratamiento del dolor.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013009537A MX348961B (es) 2011-02-18 2012-02-18 Compuestos de aminoindano y su uso en el tratamiento del dolor.

Country Status (15)

Country Link
US (1) US8865741B2 (es)
EP (3) EP3363437B8 (es)
JP (1) JP6184328B2 (es)
KR (4) KR101938684B1 (es)
CN (2) CN103547566B (es)
AU (5) AU2012219254B2 (es)
BR (1) BR112013020874A2 (es)
CA (1) CA2826648C (es)
DK (2) DK2675787T3 (es)
ES (2) ES2898910T3 (es)
IL (1) IL227967A (es)
MX (2) MX348961B (es)
RU (2) RU2612959C2 (es)
UA (1) UA112769C2 (es)
WO (1) WO2012112969A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6130383B2 (ja) 2011-09-30 2017-05-17 エンドゥ ファーマシューティカルズ，インコーポレイティド ピリジン誘導体
ES2596215T3 (es) 2011-10-24 2017-01-05 Asana Biosciences, Llc Ciclohexilaminas
WO2014028675A1 (en) * 2012-08-15 2014-02-20 Endo Pharmaceuticals Inc. Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
CN108902893B (zh) 2013-02-08 2022-02-25 通用磨坊公司 低钠食品
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
CN106214678B (zh) * 2016-07-26 2020-12-29 上海璃道医药科技有限公司 苯酮类药物的用途
EP3886827A4 (en) * 2018-11-30 2022-08-31 Asana BioSciences, LLC FORMULATIONS, METHOD, KIT AND DOSAGE FORMS TO IMPROVE STABILITY OF A PHARMACEUTICAL INGREDIENT
CN113816870B (zh) * 2021-08-25 2023-10-31 沈阳药科大学 一种快速提取不同山椒素单体的方法
WO2025245656A1 (en) 2024-05-27 2025-12-04 Libertas Bio, Inc. Crystalline solid forms of sodium channel blockers
WO2026044692A1 (en) * 2024-08-30 2026-03-05 Libertas Bio, Inc. Crystalline solid forms of indane compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE760018A (fr) 1969-12-19 1971-06-08 Christiaens Sa A Nouveau derives du 2-amino-indane, leur preparation et leur utilisation
ZA738419B (en) * 1972-11-06 1974-09-25 Christiaens Sa A New derivatives of 2-aminoindane,the preparation and use thereof
US5411738A (en) 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
US5190956A (en) 1990-09-07 1993-03-02 Schering Corporation Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections
US5344836A (en) 1991-11-11 1994-09-06 Ono Pharmaceutical Co., Ltd. Fused benzeneoxyacetic acid derivatives
EP0804434A1 (en) 1994-08-02 1997-11-05 MERCK SHARP & DOHME LTD. Azetidine, pyrrolidine and piperidine derivatives
JP3471122B2 (ja) 1995-04-26 2003-11-25 アルケア株式会社 医療用粘着配合物
GB9523243D0 (en) 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
SE508357C2 (sv) 1996-01-02 1998-09-28 Kay Laserow Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta
GB9610979D0 (en) 1996-05-24 1996-07-31 Merck Sharp & Dohme Therapeutic agents
WO1998024428A1 (en) * 1996-12-02 1998-06-11 Brigham & Women's Hospital, Inc. Long-acting local anesthetics
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
US6623040B1 (en) 1997-09-03 2003-09-23 Recot, Inc. Method for determining forced choice consumer preferences by hedonic testing
NZ515143A (en) * 1999-06-10 2004-05-28 Bridge Pharma Inc Aminoindane piperidine compounds as dermal anesthetic agents
CN1814589A (zh) * 1999-06-10 2006-08-09 布里奇药品有限公司 皮肤麻醉剂
AU5895500A (en) 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
US6630451B1 (en) 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
WO2001005767A1 (en) 1999-07-20 2001-01-25 Novartis Ag Organic compounds
AU1309701A (en) 1999-11-15 2001-05-30 Nissan Chemical Industries Ltd. Hydrazone compounds and pesticides
EP1326865B1 (en) 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
AU2001296828B2 (en) 2000-10-13 2005-11-24 Alza Corporation Apparatus and method for piercing skin with microprotrusions
CA2427381A1 (en) 2000-10-26 2002-11-28 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
US6766319B1 (en) 2000-10-31 2004-07-20 Robert J. Might Method and apparatus for gathering and evaluating information
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
HUP0402245A3 (en) 2001-11-01 2010-03-29 Janssen Pharmaceutica Nv Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
PT1321139E (pt) 2001-12-21 2007-01-31 Chiesi Farma Spa Derivados de 2-indanilamino para a terapêutica da cor crónica
PL372295A1 (en) 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
AU2003296984A1 (en) 2002-12-13 2004-07-09 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
WO2004080968A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
US7718674B2 (en) * 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
WO2006037047A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1848498A4 (en) 2004-11-18 2009-12-16 Transpharma Medical Ltd ASSOCIATED MICRO-CHANNEL PRODUCTION AND IONTOPHORESIS FOR TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS
CA2622418A1 (en) * 2005-09-23 2007-04-05 Bridge Pharma, Inc. Indanylamines and their use for local anesthesia and chronic pain
AU2006306146A1 (en) * 2005-10-28 2007-05-03 Abbott Laboratories Indazole derivatives that inhibit TRPV1 receptor
GB0525029D0 (en) 2005-12-08 2006-01-18 Univ Hull Receptor Antagonist
TWI409256B (zh) 2006-09-01 2013-09-21 Dow Agrosciences Llc 殺蟲性之ｎ-取代（雜芳基）環烷基磺醯亞胺
TWI383970B (zh) 2006-11-08 2013-02-01 Dow Agrosciences Llc 多取代的吡啶基磺醯亞胺及其作為殺蟲劑之用途
KR20090082507A (ko) 2006-11-20 2009-07-30 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 통증 및 소양증 치료용 방법, 조성물 및 키트
CN101605760B (zh) 2007-02-09 2012-06-20 陶氏益农公司 将某些取代的硫亚胺氧化为杀虫性磺基肟的方法
US7511149B2 (en) 2007-02-09 2009-03-31 Dow Agrosciences Llc Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines
WO2008099022A1 (en) 2007-02-16 2008-08-21 Tibotec Pharmaceuticals Ltd. 10-sulfonyl-dibenzodiazepinones useful as hepatitis c virus inhibitors
EP2225237A2 (de) 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organische verbindungen
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
EP2225223B1 (de) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organische verbindungen
WO2009065921A2 (de) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organischeverbindungen
CN102112121A (zh) 2008-03-11 2011-06-29 哈佛大学校长及研究员协会 用于治疗疼痛和瘙痒的方法、组合物和药盒
AU2009283085A1 (en) 2008-08-20 2010-02-25 Merck Sharp & Dohme Corp. Non-amidic linkers with branched termini as CGRP receptor antagonists
WO2011006073A1 (en) 2009-07-10 2011-01-13 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents

Also Published As

Publication number Publication date
US8865741B2 (en) 2014-10-21
KR101938684B1 (ko) 2019-01-16
ES2675510T3 (es) 2018-07-11
RU2612959C2 (ru) 2017-03-14
CN103547566A (zh) 2014-01-29
ES2898910T3 (es) 2022-03-09
EP2675787B1 (en) 2018-03-28
CA2826648C (en) 2019-06-04
KR20180079459A (ko) 2018-07-10
US20120214809A1 (en) 2012-08-23
AU2016256819A1 (en) 2016-12-01
EP3970723A1 (en) 2022-03-23
HK1248704A1 (zh) 2018-10-19
AU2016256819B2 (en) 2018-08-09
AU2012219254A1 (en) 2013-08-29
EP3363437B8 (en) 2021-11-03
CA2826648A1 (en) 2012-08-23
AU2023202157A1 (en) 2023-05-04
RU2013142433A (ru) 2015-03-27
MX2013009537A (es) 2014-01-08
AU2020277232B2 (en) 2023-01-12
IL227967A0 (en) 2013-09-30
CN103547566B (zh) 2017-05-31
AU2016256819C1 (en) 2019-02-21
KR20140021553A (ko) 2014-02-20
AU2023202157B2 (en) 2024-10-31
IL227967A (en) 2017-04-30
AU2018260936B2 (en) 2020-08-27
RU2016151688A (ru) 2018-11-15
AU2020277232A1 (en) 2020-12-24
AU2020277232C1 (en) 2023-08-03
JP6184328B2 (ja) 2017-08-23
KR102014203B1 (ko) 2019-08-26
DK3363437T3 (da) 2021-11-01
RU2016151688A3 (es) 2020-03-06
CN107540599A (zh) 2018-01-05
AU2012219254B2 (en) 2016-08-11
JP2014505739A (ja) 2014-03-06
UA112769C2 (uk) 2016-10-25
KR102173572B1 (ko) 2020-11-03
EP3363437B1 (en) 2021-07-28
KR20190101481A (ko) 2019-08-30
CN107540599B (zh) 2021-06-04
EP3363437A1 (en) 2018-08-22
MX348961B (es) 2017-07-04
DK2675787T3 (en) 2018-07-16
EP2675787A1 (en) 2013-12-25
WO2012112969A1 (en) 2012-08-23
AU2018260936A1 (en) 2018-11-29
KR20200125765A (ko) 2020-11-04
BR112013020874A2 (pt) 2019-05-21

Similar Documents

Publication Publication Date Title
MX348961B (es) Compuestos de aminoindano y su uso en el tratamiento del dolor.
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
NZ715747A (en) Syk inhibitors
EA201391644A1 (ru) Частично насыщенные трициклические соединения и способы их получения и применения
PH12016501204B1 (en) Syk inhibitors
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
NZ726366A (en) Syk inhibitors
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
MX388946B (es) Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos.
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201590562A1 (ru) Бензамиды
EA201270808A1 (ru) Новые формы рифаксимина и их применение
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201590697A1 (ru) Производные кетамина
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201590522A1 (ru) Способы введения рифаксимина для снижения веса и лечения ожирения
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
EA201491878A1 (ru) Замещенные ксантиновые производные